Literature DB >> 8158105

Primary human herpesvirus-6 infection is frequently overlooked as a cause of febrile fits in young children.

K N Ward1, J J Gray.   

Abstract

Sera from 248 children aged 30-179 weeks were tested retrospectively for human herpesvirus-6 (HHV-6) IgG antibody avidity. Twenty-five children presented with febrile fits, in one case with a rash, exanthem subitum resulting from primary HHV-6 infection was diagnosed at the time, but in the others HHV-6 was not considered in the differential diagnosis even though two patients had a rash. In fact, five of the 25 patients experienced primary infection as shown by low avidity HHV-6 antibody. Although nine other of these patients were seronegative in the acute phase of the illness, and unfortunately convalescent sera were not available to confirm primary HHV-6 infection, seronegativity was clearly a risk factor for febrile fits (P = 0.03, odds ratio 3.14 for all children; P = 0.002, odds ratio 7.20 for children aged 70-179 weeks), and primary HHV-6 infection was a very likely diagnosis. The remaining 11 children had high avidity antibody, so HHV-6 was excluded as a cause of their febrile fits. HHV-6 may frequently be a cause of febrile fits, often without the typical rash of exanthem subitum, and this diagnosis is often overlooked by clinicians.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8158105     DOI: 10.1002/jmv.1890420204

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

Review 1.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Diagnosis of primary human herpesvirus 6 and 7 infections in febrile infants by polymerase chain reaction.

Authors:  D A Clark; I M Kidd; K E Collingham; M Tarlow; T Ayeni; A Riordan; P D Griffiths; V C Emery; D Pillay
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

3.  Human herpesvirus 6 DNA levels in cerebrospinal fluid due to primary infection differ from those due to chromosomal viral integration and have implications for diagnosis of encephalitis.

Authors:  Katherine N Ward; Hoe Nam Leong; Anton D Thiruchelvam; Claire E Atkinson; Duncan A Clark
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

4.  Use of immunoglobulin G antibody avidity for differentiation of primary human herpesvirus 6 and 7 infections.

Authors:  K N Ward; D J Turner; X C Parada; A D Thiruchelvam
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

Review 5.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland.

Authors:  K N Ward; N J Andrews; C M Verity; E Miller; E M Ross
Journal:  Arch Dis Child       Date:  2005-06       Impact factor: 3.791

7.  Variation in human herpesvirus 6B telomeric integration, excision, and transmission between tissues and individuals.

Authors:  Michael L Wood; Colin D Veal; Rita Neumann; Nicolás M Suárez; Jenna Nichols; Andrei J Parker; Diana Martin; Simon Pr Romaine; Veryan Codd; Nilesh J Samani; Adriaan A Voors; Maciej Tomaszewski; Louis Flamand; Andrew J Davison; Nicola J Royle
Journal:  Elife       Date:  2021-09-21       Impact factor: 8.140

8.  Did a then unknown virus, HHV-6/7, give rise to the whooping cough vaccine controversy of the 1970s?

Authors:  Philip P Mortimer
Journal:  Epidemiol Infect       Date:  2016-06-23       Impact factor: 4.434

9.  Detection of HHV-6 and EBV and Cytokine Levels in Saliva From Children With Seizures: Results of a Multi-Center Cross-Sectional Study.

Authors:  Luca Bartolini; Eleonora Piras; Kathryn Sullivan; Sean Gillen; Adrian Bumbut; Cheng-Te Major Lin; Emily C Leibovitch; Jennifer S Graves; Emmanuelle L Waubant; James M Chamberlain; William D Gaillard; Steven Jacobson
Journal:  Front Neurol       Date:  2018-10-05       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.